- Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal
- Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC
- Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients. The Stock Is Up. Barron’s
- Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company
- Eli Lilly’s oral GLP-1 pill may help people with Type 2 diabetes lose ‘significant’ weight, study finds ABC News
Source link